APA

Saigi E., Salut A., Campos J. M., Losa F., Manzano H., Batiste-Alentorn E., Acusa A., Vélez de Mendizabal E., Guasch I. & Antón I. (20050422). Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors. : Anti-cancer drugs.

Chicago

Saigi Eugeni, Salut Antonieta, Campos Juan Manuel, Losa Ferran, Manzano Hermini, Batiste-Alentorn Eduard, Acusa Angels, Vélez de Mendizabal Edelmira, Guasch Inmaculada and Antón Isabel. 20050422. Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors. : Anti-cancer drugs.

Harvard

Saigi E., Salut A., Campos J. M., Losa F., Manzano H., Batiste-Alentorn E., Acusa A., Vélez de Mendizabal E., Guasch I. and Antón I. (20050422). Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors. : Anti-cancer drugs.

MLA

Saigi Eugeni, Salut Antonieta, Campos Juan Manuel, Losa Ferran, Manzano Hermini, Batiste-Alentorn Eduard, Acusa Angels, Vélez de Mendizabal Edelmira, Guasch Inmaculada and Antón Isabel. Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors. : Anti-cancer drugs. 20050422.